CoChat

Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Abstract

Few trials of glucose-lowering drugs or strategies in people with type 2 diabetes have investigated cardiovascular outcomes, even though most patients die from cardiovascular causes despite the beneficial effects of lipid-reducing and blood pressure-lowering treatments. The evidence-based reduction in risk of microvascular disease with glucose lowering has resulted in guidelines worldwide recommending optimisation of glycosylated haemoglobin, but no trial results have shown unequivocal cardiovascular risk reduction with glucose lowering. However, results of the post-trial follow-up of the UK Prospective Diabetes Study, and of a meta-analysis of the four glucose-lowering outcome trials completed to date, suggest about a 15% cardiovascular relative risk reduction per 1% decrement in HbA1c. The 2008 US Food and Drug Administration industry guidance for licensing of antidiabetic drugs greatly increased the number of cardiovascular outcome trials in diabetes, but most trials opted for non-inferiority designs aiming primarily to show absence of cardiovascular toxicity in the shortest possible time. This unintended consequence of the new regulations has meant that the potential long-term benefits, and the possible risks of new therapies, are not being assessed effectively. Also, essential head-to-head trials of therapies for this complex progressive disease, to answer issues such as how best to achieve and maintain optimum glycaemia without promoting weight gain or hypoglycaemia, are not being undertaken. In this Series paper, we summarise randomised controlled cardiovascular outcome trials in type 2 diabetes, provide an overview of ongoing trials and their limitations, and speculate on how future trials could be made more efficient and effective.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(14)60794-7

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 53 references

Research works printed but not linked: 1

  1. Bethel, 2012, Positive impact of revised FDA guidance on clinical trial design in diabetes (abstr), Diabetes, 61, A264

Cited by

See all 241

Metadata

Authors
Holman, R. R., Sourij, H., & Califf, R. M.
Affiliations
  • University of Oxford (GB)
  • Medical University of Graz (AT)
  • Duke University (US)
Corresponding author
Holman, Rury R
Venue
The Lancet
Publisher
Elsevier BV
Published
2014-06
Volume
383
Issue
9933
Pages
2008-2017
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2069397244
Cited by
227
References
53
Citations by year
2026: 3 · 2025: 10 · 2024: 7 · 2023: 6 · 2022: 7 · 2021: 11 · 2020: 20 · 2019: 8 · 2018: 22 · 2017: 34 · 2016: 52 · 2015: 36 · 2014: 11
FWCI
7.04
Type
journal article
Language
en
Update notices
erratum (2014-06-28)
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
type 2 diabetes, cardiovascular outcome trials, antidiabetic drugs, cardiovascular risk reduction, HbA1c, glycemic control, trial design limitations, UK Prospective Diabetes Study
MeSH terms
Diabetes Mellitus, Type 2, Diabetic Angiopathies, Follow-Up Studies, Forecasting, Humans, Hypoglycemic Agents, Randomized Controlled Trials as Topic, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. https://app.cochat.ai/papers/10.1016/s0140-6736(14)60794-7
The paper
Holman, R. R., Sourij, H., & Califf, R. M. (2014). Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. The Lancet. https://doi.org/10.1016/s0140-6736(14)60794-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.